The document outlines key messages about chronic IBS (C-IBS) to communicate to doctors. It notes that C-IBS patients predominantly experience abdominal pain, bloating, and constipation, which fluctuate and decrease quality of life. It emphasizes that IBS significantly impacts quality of life, is highly prevalent and costly, and is a serious condition requiring treatment to improve patients' quality of life. Finally, it positions Zelmac as the only treatment that addresses the underlying cause of C-IBS by working in three ways to provide rapid and sustained relief of multiple C-IBS symptoms.